公开(公告)号：US20240316085A1

公开(公告)日：2024-09-26

申请号：US18444468

申请日：2024-02-16

Applicant: Tulavi Therapeutics, Inc.

Inventor： Corinne Bright ,  Kondapavulur T. Venkateswara-Rao ,  Emily Stein

IPC: A61K31/704 ,  A61K9/00 ,  A61K31/135 ,  A61K31/445 ,  A61N1/36

CPC classification number: A61K31/704 ,  A61K9/0019 ,  A61K31/135 ,  A61K31/445 ,  A61N1/36114

Abstract: Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.

公开(公告)号：US11446359B2

公开(公告)日：2022-09-20

申请号：US16275120

申请日：2019-02-13

Applicant: Tulavi Therapeutics, Inc.

Inventor： Corinne Bright

IPC: A01N43/00 ,  A01N43/46 ,  A61K31/55 ,  A61K38/21 ,  A61N5/02 ,  A61B18/14 ,  A61B90/30 ,  A61B17/34 ,  A61K45/06 ,  A61B8/12 ,  A61B18/18 ,  A61K31/4422 ,  A61K31/475 ,  A61K47/10 ,  A61K9/06 ,  A61K47/36 ,  A61K9/51 ,  A61K31/045 ,  A61K31/19 ,  A61K31/337 ,  A61N7/02 ,  A61L27/18 ,  A61L27/52 ,  A61L27/56 ,  A61L31/06 ,  A61L31/14 ,  A61P9/00 ,  A61P29/02 ,  A61P25/02 ,  A61B18/00 ,  A61B8/08 ,  A61N7/00

Abstract: Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4/5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

公开(公告)号：US11246879B2

公开(公告)日：2022-02-15

申请号：US16076308

申请日：2017-02-09

Applicant: Tulavi Therapeutics, Inc.

Inventor： Corinne Bright ,  Kondapavulur T. Venkateswara-Rao ,  Emily Stein

IPC: A61K31/704 ,  A61K31/445 ,  A61N1/36

Abstract: Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.

公开(公告)号：US20210268271A1

公开(公告)日：2021-09-02

申请号：US17257266

申请日：2019-07-02

Applicant: Tulavi Therapeutics, Inc.

Inventor： Corinne BRIGHT

IPC: A61N1/05 ,  A61N1/06 ,  A61K9/06 ,  A61K47/14 ,  A61K47/10 ,  A61K47/34

Abstract: Methods, devices and systems are described for gel-based modulation of neural tissue, including prevention of nerve regeneration and neuroma formation. The gel can be delivered to selected target locations including the myenteric plexus.

公开(公告)号：US20210205501A1

公开(公告)日：2021-07-08

申请号：US16981199

申请日：2019-03-15

Applicant: Tulavi Therapeutics, Inc.

Inventor： Corinne Bright

IPC: A61L27/54 ,  A61N7/02 ,  A61L27/52 ,  A61L27/18 ,  C08L71/02

Abstract: Methods, devices and systems are described for gel-based modulation of neural tissue, including prevention of nerve regeneration and neuroma formation. The gel can be delivered to selected target locations within or proximate nerves, including interfascicularly and intrafascicularly. Gel delivery associated with an operative procedure for the treatment of pain and other indications is also disclosed.

公开(公告)号：US20210187160A1

公开(公告)日：2021-06-24

申请号：US17138703

申请日：2020-12-30

Applicant: Tulavi Therapeutics, Inc. ,  Incept, LLC

Inventor： Corinne BRIGHT ,  Yong REN ,  Kenneth M. MARTIN ,  Farhad KHOSRAVI ,  Amarpreet S. SAWHNEY

IPC: A61L27/26 ,  A61L27/18 ,  A61L27/52

Abstract: Disclosed are methods, devices and materials for the in situ formation of a nerve cap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth

公开(公告)号：US11944717B2

公开(公告)日：2024-04-02

申请号：US17477947

申请日：2021-09-17

Applicant: Tulavi Therapeutics, Inc. ,  Incept, LLC

Inventor： Corinne Bright ,  Yong Ren ,  Kenneth M. Martin ,  Farhad Khosravi ,  Amarpreet S. Sawhney

IPC: A61B17/11 ,  A61B17/00 ,  A61F2/00 ,  A61F2/02 ,  A61K9/00 ,  A61L27/18 ,  A61L27/26 ,  A61L27/52 ,  A61L31/14

CPC classification number: A61L27/26 ,  A61B17/1128 ,  A61F2/00 ,  A61F2/02 ,  A61K9/0004 ,  A61L27/18 ,  A61L27/52 ,  A61L31/14 ,  A61B2017/00526 ,  A61F2210/00 ,  A61F2210/008 ,  A61F2240/00 ,  A61F2240/001 ,  A61F2250/00 ,  A61L2400/06 ,  A61L2430/32

Abstract: Disclosed are methods, devices and materials for the in situ formation of a nerve cap and/or a nerve wrap to inhibit neuroma formation following planned or traumatic nerve injury. The method includes the steps of identifying a severed end of a nerve, and positioning the severed end into a cavity defined by a form. A transformable media is introduced into the form cavity to surround the severed end. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the severed end. The media may be a hydrogel, and the transformation may produce a synthetic crosslinked hydrogel protective barrier. The media may include at least one anti-regeneration agent to inhibit nerve regrowth.

公开(公告)号：US11918595B2

公开(公告)日：2024-03-05

申请号：US17669778

申请日：2022-02-11

Applicant: Tulavi Therapeutics, Inc.

Inventor： Corinne Bright ,  Kondapavulur T. Venkateswara-Rao ,  Emily Stein

IPC: A61K9/00 ,  A61K31/135 ,  A61K31/445 ,  A61K31/704 ,  A61N1/36

CPC classification number: A61K31/704 ,  A61K9/0019 ,  A61K31/135 ,  A61K31/445 ,  A61N1/36114

Abstract: Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.

公开(公告)号：US20220370345A1

公开(公告)日：2022-11-24

申请号：US17669778

申请日：2022-02-11

Applicant: Tulavi Therapeutics, Inc.

Inventor： Corinne Bright ,  Kondapavulur T. Venkateswara-Rao ,  Emily Stein

IPC: A61K9/00

Abstract: Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.

公开(公告)号：US20210361292A1

公开(公告)日：2021-11-25

申请号：US17388327

申请日：2021-07-29

Applicant: Tulavi Therapeutics, Inc. ,  INCEPT, LLC

Inventor： Corinne Bright ,  Yong Ren ,  Ken Martin ,  Farhad Khosravi ,  Amarpreet S. Sawhney

IPC: A61B17/12 ,  A61F2/08 ,  A61F2/00 ,  A61F2/02

Abstract: Disclosed are methods, devices and materials for the in situ formation of an implant for treating a nerve. A treatment site on a nerve is positioned within a cavity defined by a form. A transformable media is introduced into the form cavity to surround the treatment site. The media is permitted to undergo a transformation from a first, relatively flowable state to a second, relatively non flowable state to form a protective barrier surrounding the treatment site. The implant may be a growth inhibiting nerve cap to inhibit neuroma formation following planned or traumatic nerve injury, a growth permissive conduit for facilitating reconnection of a severed nerve, or an anchor for stabilizing a pain management electrode with respect to a nerve. Access to the nerve treatment site may be open surgical or percutaneous.